logo-loader

Quellthera developing 'groundbreaking' therapy to slow drug-resistant superbugs

Published: 18:15 09 Jan 2019 AEDT

Quellthera Inc CEO Alex Huang sat down with Proactive Investors at the 11th Annual Biotech Showcase in San Francisco.

San Francisco Bay Area based Quellthera is addressing the growing threat of antibiotic resistant disease with EpiQuell, a novel concept in anti–pathogenic therapies that harnesses the plant kingdom’s evolution-proven ability to control bacterial behavior. The company believes EpiQuell will slow, if not reverse, the emergence of drug-resistant superbugs.

Australian Strategic Materials signs US$600 million LoI

Rowena Smith, CEO and managing director of Australian Strategic Materials Ltd (ASX:ASM, OTC:ASMMF), joins Jonathan Jackson in the Proactive studio to discuss the company’ s Dubbo Project, in Central West New South Wales. This project aims to extract and process critical minerals and rare earth...

9 hours, 57 minutes ago